Meet in Italy for Life Sciences 2018 Brokerage Event – MIT4LS2018 BE Participants Catalogue 1st October Update 443 Participants MIT4LS2018 BE Dates to remember 01 Oct 2018*, midnight Deadline for registration *Registrations can be closed earlier depending on the number of participants 19 Sep - 03 Oct 2018, 14:00 Book Face2Face meetings 05 Oct 2018 Release of first version of meeting schedule 10 Oct 2018 11:00 – 18:30 Bilateral face-2-face meetings 11 Oct 2018 09:30 – 18:30 Bilateral face-2-face meetings een.ec.europa.eu 3C Engineering Organisation Country Italy City Roma Street Via Riccardo Pitteri,32 Web http://www.3cengineering.it Person Name Fabio Buccolini (3C Engineering Srls) 3C Engineering Organisation Start up with holistic approach to the IT sector with a vision based on ameliorating the quality of life using technologies. Web platforms, domotics, cybersecurity and App development are the business field of the Start-Up since mid 2018 is also focusing the healthcare sector. In particular for healthcare sector has been developed an IT system (web platform and App) based of Patents Granted and Copyright for CISD able to evaluate Psoriasis and atopic dermatitis increasing the patients quality of life . Areas of Activity • Bioinformatics, Big data analytics • Medical devices • Consulting services • IT Applications for Health • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Software, ICT applications, system integration Marketplace Opportunities PRODUCT PSORINO : V-PASI Psoriasis Index PSORINO is an innovative App solution for dermatologists based on a robust new patented technique helpful in the management of treatment plan of PSORIASIS. The patented method and V-PASI Score is very useful in the management of biological therapies, when psoriasis is in complete remission and a customized therapy is required to maintain the remission of the pathology. Finally the App has also the "placebo" effect tools due the autodiagnosis opportunity evaluated by the Dermatologists in a typical telemedicine model. PARTNERSHIP CRO & Cinical Trials The App and its back-end is very useful at R&D level for the evaluation of Pharmaceutical products for 2 / 880 Psoriasis . It is a perfect tool for Clinical Trials able to match data with the PAASI score and V-PASI score considering its micro-measurements. PROJECT COOPERATION H2020 EU Projects focusing CISD and Inflammatory Pathologies The Start-Up is available to evaluate possible partnerships for 2019 applications accordingly with the H2020 Call for Proposals (NO SME Instrument) in the Healthcare sector. INVESTMENT OPPORTUNITY Growth of the ICT infrastructure Teh Start-Up with this new products App PSORINO is available for inverstors (equity) 3 / 880 A Menarini IFR Organisation Country Italy City Pomezia Street Via Tito Speri, 10 Web https://www.menarini.it/ Person Name Claudio Panzarella Head of Biopharmaceuticals Licensing In Organisation Menarini's delegates will be available for discussions at the workshop "A glance into solution provided by the Menarini Group" that will take place in Oct, 10th at 11,30 am in Didattica B Room. Please come to visit us also at the exposition booth located in the conference center. The Menarini Group is one of Europe’s 15 leading pharmaceutical companies, headquartered in Florence, Italy with global operations powered by more than 17,000 employees generating a turnover of around €4b in 2017. Its rapid international business expansion with more than 100 affiliates and partners, advocates its global reach. Leader in commercial excellence both in Specialist and PCP with an unsurpassed partnering track- record based on generating value and trust. The focus of the privately-owned company is researching, developing, manufacturing and marketing medications of high therapeutic value for patients. It is committed in these key areas: oncology, anti-infectives, pain, respiratory and cardiovascular. Menarini's research activities are carried out throughout its 6 fully-integrated R&D centers in Europe and Singapore in addition to 16 manufacturing plants throughout the globe. The Menarini Group is composed of Pharmaceuticals, Diagnostics and Consumer Health. Areas of Activity • Biotechnologies (Pharma&Medical • Manufacturing & process engineering Devices) • Pharmaceutics • CMO (Contract Manufacturing Organisation) • CRO (Contract Research Organisation) • Drug screening & delivery Marketplace Opportunities PARTNERSHIP Collaboration, licensing-in opportunities with Menarini Menarini IFR is looking for potential partnership, collaboration, licensing-in opportunities in pharma, biopharma, diagnostics and consumer health in the key areas: oncology, anti-infectives, pain, respiratory and cardiovascular. Please come to visit us also at the exposition booth located in the conference center. 4 / 880 A.I.S.M.O. Onlus Organisation Country Italy City Roma Street Via E.d'Arborea 38 Web www.aismo.it Person Name Virginia A. Prof.Cirolla Presidente Nazionale Organisation The Association AISMO is involved in research, treatment and rehabilitation of patientswith cancer and it is committed in supporting their familiesin the different phases of treatment planning and care. One of its focus is thecancer pain treatment of oncological patients. The association has different branches in Italy, with its headquarter in Rome.http://www.aismo.it Areas of Activity • Biomaterials • Medical research • Biosensors • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Medical devices • Chemicals & APIs • Diagnostics IVD • Diagnostics - Equipment and accessories Marketplace Opportunities PRODUCT Nanotechnologies and Oncological Research Drugs development for cancer treatment FUNDING PROGRAMME AND REFERENCE Nanosciences Oncological Diseases Research TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE Universities 5 / 880 A.Menarini Diagnostics Organisation Country Italy City Bagno a Ripoli (FI) Street Via Lungo L'Ema, 7 Web http://www.menarini.com Person Name Fabrizio Mastrantonio Global Scientific Marketing Affairs Manager Organisation A.Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded Naples in 1886 and then moved to Florence in 1915. Today it is the leading Italian pharmaceutical company in the world, ranking 16th in Europe (among 5.291 companies) and 38th in the world (among 19.042 companies) IMS World Review 2013). Present in over 130 countries throughout the world, today it counts 16,603 employees and has a 2013 turnover of over € 3,27 billion (US$ 3.7 billion). Menarini Group is the 1st pharmaceutical group in Southern Europe (market share 4.5%) and the first in Italy (market share 8.6%). The A. Menarini Diagnostics Srl was founded in 1976 and began developing and manufacturing its own products in 1982. A Quality Control Department and a Research & Development laboratory have been added since then. A.Menarini Diagnostics has a European-wide corporate organisation. The present structure of Menarini Diagnostics is made up of its Headquarters in Florence and a network of fourteen fully owned affiliates in the following countries: Portugal, Spain, France, UK (Eire), Sweden, Belgium, Netherlands, Germany, Switzerland, Austria, Russia, Italy and Greece. A.Menarini Diagnostics is the biggest Italian company in the In Vitro Diagnostics (IVD) market and the most "internationally oriented" Italian company as far as the number of direct affiliates in Europe is concerned. From July 1997 onwards, A.Menarini Diagnostics has been certified by TÜV in accordance with the ISO 9002 and EN 46002 standard requirements and is currently certified to ISO 9001:2008 and ISO13485:2003standards by TÜV SUD. A.Menarini Diagnostics employs approximately 900 people, 600 of which (approximately 67%) are in the marketing and sales areas while another 125 (almost 14%) are employed in the technical service departments. The turnover for the year 2015 was approximately 250 million Euro (US$ 282 miilion). The strategic areas of A.Menarini Diagnostics are: Diabetes (self testing, POCT and laboratory systems), Clinical Chemistry (laboratory and POCT), Urinalysis &Sediment Analysis, CellPathology&Cytology, Autoimmunity and Molecolar Biology. A.Menarini Diagnostics is strongly and actively engaged in the field of diabetes. Its activities include educational programmes for diabetic patients, advanced systems for the monitoring of diabetes (Glucocard and GlucoMen® systems), the automatic determination of glycated proteins, including glycated haemoglobin, and research which aims at the identification of new devices for the prognosis, the diagnosis and the monitoring of the disease. Since 2001, A.Menarini Diagnostics is involved in the Continuos Glucose Monitoring through the 6 / 880 GlucoDay® / GlucoMen® Day system, a glucose holter which is able to continuously monitor the glucose concentration for a period up to 5 days using the micro-dialysis technology via a subcutaneous microfibre. GlucoDay® has the dimension of a small “walkman” and allows the patient to carry on a normal life style even during the test. The system has been CE-MD marked by the TÜV Product Service notify body. A.Menarini Diagnostics’ main activities are concentrated in Europe where it is ranked 9th in the In-Vitro Diagnostic market. According to “Clinica MedTech 2012 Top 100”, Menarini Diagnostics is ranked at 91st position in the world-wide MedTech market and at the 20th position in the world-wide In-Vitro Diagnostic market, even if mainly